Patients of all ages and genders regularly experience urinary tract infections. Antibiotic misuse has caused organisms to develop drug resistance, creating a treatment problem. Objective: To uncover risk variables and relationships, as well as the antibiotic susceptibility in UTI patients. Methods: Diabetes and non-diabetes with UTI were compared within groups using the Chi-square test, with a significant P-value of 0.05. Results: 32 (21.2%) were given empirical treatment with ciprofloxacin (11%), cefixime (5%), ceftriaxone (2.6%), cefoparazone-sulbactum (1.30%), amoxicillin-clavulanic acid (1.30%), ampicillin (1.30%), and co-trimoxazole (0.60%), respectively. E. coli was the most prevalent pathogen, with an isolation rate of 84%, followed by pseudomonas aeruginosa (6%), Serratia (3.3%), klebsiella (2.6%), Enterobacter cloacae (2.6%), Sternotophomus (0.7%), and MRSA (each in 0.7%). Ampicillin, Cefixime, Ceftriaxone, Co-Trimoxazole, Ciprofloxacin, Amoxicillin-Clavulanic Acid, Tetracycline, and Levofloxacin were all often resistant to, respectively, 87 percent, 83 percent, 78 percent, 78 percent, and 51 percent of these antibiotics. Conclusions: MDR prevalence is highest in gram-negative bacteria. The presence of diabetes mellitus and being a woman are significant risk factors for UTI, according to tests. Escherichia coli (84%) is the most common uropathogen. Carbapenems, piperacillin-tazobactam, Amikacin, Gentamicin, and cefoparazone-sulbactam (parenteral) as well as Nitrofurantoin are the preferred empirical treatments (oral). Hospitals and the nation at large should constantly examine and reassess their antimicrobial policies.
Read full abstract